Results 81 to 90 of about 435,111 (310)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

A Guidance Manual for the Toxicity Assessment of Traditional Herbal Medicines

open access: yesNatural Product Communications, 2016
Herbal remedies have been used for thousands of years in worldwide traditional medicines for their potential health benefits. Although they are generally presumed safe unless a significant risk has been identified in humans, increasing number of case ...
Ahmet Aydιn   +2 more
doaj   +1 more source

The study of an acute toxicity of extracts from Veronica teucrium L. and from Veronica longifolia L.

open access: yesAktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2018
The aim of our work were to study the acute toxicity of extracts obtained from herb, leaves, flowers of V. teucrium L. and from herb of V. longifolia L. Materials and methods.
А. Р. Osmachko   +4 more
doaj   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

open access: yesMolecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu   +10 more
wiley   +1 more source

Determining safety of betacarboclomet cream in epidermal delivery to the body of animals

open access: yesAktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2015
Aim. The article is devoted to safety determining of newly developed drug as one of the important stages of preclinical evaluation in the organization of industrial manufacturing. Methods and results.
G. M. Voytenko   +3 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

DETECTIVE: Detection of Endpoints and Biomarkers for Repeated Dose Toxicity using in vitro Systems

open access: yes, 2022
136165Assessment of repeated dose toxicity is a standard requirement in human safety evaluation and relies on animal testing as no alternatives are currently accepted for regulatory purposes.
Stöber, R.   +20 more
core  

Compliance to HIV treatment monitoring guidelines can reduce laboratory costs

open access: yesSouthern African Journal of HIV Medicine, 2016
Background: Panel tests are a predetermined group of tests commonly requested together to provide a comprehensive and conclusive diagnosis, for example, liver function test (LFT).
Naseem Cassim   +3 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy